Discovery Programs

Target Discovery

Our in-house developed platform preDict uses AI and machine learning for its target discovery. The platform enables a rapid biological and data-driven approach to target discovery and target validation.

Why choose Gubra?

Track record of ingenuity-based target discovery
Streamlined database
Rapid off-the-shelf translational models
Integrative target discovery qualification and validation
Discovery on your target

Consult with Sebastian M.N. Heimbürger

Manager, Business Development

Join forces with Gubra, a trustworthy discovery partner.

AI-driven target discovery & rapidly qualified in vivo PoC

Target Discovery

Streamline for Target Discovery 
The preDict platform combines state-of-the-art translational preclinical data to identify novel druggable targets.

Target Qualification

Powered by algorithms
The preDict‘s algorithm identifies and ranks targets based on algorithms, using advanced analytical methods such as RNAseq, scRNAseq, AI-assisted histopathology and biochemical assays on samples.

Target Validation

Strong hit rate
Several novel targets have already been identified using our preDict platform and validated in our in vivo pharmacology models.

“

The preDict platform enables flexible inter-organ target discovery

preDict unifies various types of data with advanced AI, machine-learning, and scientific ingenuity fueling holistic insights into biology and data-driven target discovery.

Target discovery areas

Liver

State-of-the-art preclinical NASH database
In-depth characterization of preclinical models
Partnership with Silence Therapeutics : identification of selected novel liver-directed targets (preDict)

Kidney

Preclinical and clinical database with translational models
In-depth characterization of preclinical models

CNS & Obesity

Expertise in preclinical obesity, 3D imaging and sequencing technology
Isolation and sequencing of key CNS areas for body weight set-point
Partnership with Boehringer Ingelheim : uncovering the next-generation of anti-obesity treatments (preDict)

Lungs

Translatable preclinical lungs fibrosis models for efficacy and target discovery
Database with integrated AI-histopathological Ashcroft scoring and RNA-sequencing for target prediction